Innovation at stake in PCSK9 patent battle extends beyond antibodies

Whether the Supreme Court rules in favor of Amgen or Sanofi in the high-stakes patent dispute over anti-PCSK9 mAbs, the decision will broadly affect innovation of antibody therapies, and likely extend to related modalities.

The industry remains split on which outcome will best promote or at least preserve innovation in therapeutic antibody development. Each side in the case presented arguments on the validity of the claims and the effect the decision will have on innovation, and both had support from other industry stakeholders. More than 30 amicus briefs were submitted, with most big pharmas weighing in...